«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

31卷

期数:

2025年02期

页码:

134-138

栏目:

基础医学

出版日期:

2025-03-20

文章信息/Info

Title:

Construction and identification of PTH（1-34）-induced bone mineralization experimental animal model in mice

文章编号:

1006-8147(2025)02-0134-05

作者:

王红丽; 李晓青

（天津医科大学肿瘤医院肿瘤研究所生物化学与分子生物学研究室，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床研究中心，天津市肿瘤防治重点实验室，乳腺癌防治教育部重点实验室，天津300060）

Author(s):

WANG Hongli; LI Xiaoqing

（Department of Biochemistry and Molecular Biology，Tianjin Medical University Cancer Institute and Hospital；Tianjin Medical University Cancer Institute & Hospital，National Clinical Research Center for Cancer；Tianjin′s Clinical Research Center for Cancer；Key Laboratory of Cancer Prevention and Therapy，Tianjin；Key Laboratory of Breast Cancer Prevention and Therapy，Tianjin Medical University，Ministry of Education，Tianjin 300060，China）

关键词:

甲状旁腺激素（1-34）; 骨矿化; 骨密度; 实验动物模型

Keywords:

parathyroid hormone （1-34）; bone mineralization; bone mineral density; experimental animal model

分类号:

R589.5

DOI:

-

文献标志码:

A

摘要:

目的：探讨骨骼发育及矿化过程，构建骨矿化小鼠实验动物模型。方法：采用甲状旁腺激素（PTH）（1-34）经腹腔注射，诱导6周龄NOD-SCID雌性小鼠成骨细胞分化及骨组织矿化，从而构建骨矿化小鼠实验动物模型。进一步应用Micro-CT检测骨密度，应用钙黄绿素和盐酸四环素荧光标记检测骨矿化沉积率，应用冯库萨染色鉴定钙盐沉积，并应用马松染色检测骨胶原容积分数，以鉴定小鼠骨组织矿化水平，确定骨矿化小鼠模型是否构建成功。结果：Micro-CT检测发现，PTH（1-34）诱导20 d可以显著增加骨小梁相对体积分数（BV/TV，t=9.473，P＜0.001）和骨小梁厚度（Tb.Th，t=18.64，P＜0.001），显著减少骨小梁间距（Tb.Sp，t=7.794，P＜0.01）。双荧光标记显示，PTH（1-34）处理后骨矿化沉积率（MAR）显著提高（t=29.99，P＜0.001）。冯库萨染色显示，PTH（1-34）处理组冯库萨阳性面积（VK.A）显著增加（t=2.914，P＜0.05）。马松染色显示，PTH（1-34）处理后胶原容积分数（CVF）显著提升（t=13.94，P＜0.001）。结论：PTH（1-34）可有效诱导小鼠骨骼矿化，成功构建骨矿化小鼠实验动物模型。

Abstract:

Objective：To investigate the process of bone development and mineralization，and construct an experimental animal model of bone mineralization in mice. Methods：PTH （1-34） （parathyroid hormone 1-34） was injected intraperitoneally to induce osteoblast differentiation and bone tissue mineralization in 6-week-old NOD-SCID female mice，and an experimental animal model of bone mineralization was constructed. Furthermore，micro-CT was used to detect bone mineral density，calcein and tetracycline hydrochloride fluorescent labeling was used to detect mineral apposition rate. Von Kossa staining was used to identify calcium salt deposition，and Masson staining was used to detect bone collagen volume fraction to identify the level of bone tissue mineralization in mice and determine whether the mouse model of bone mineralization was successfully established. Results：Micro-CT showed that PTH （1-34） induction for 20 days significantly increased the Bone Volume/Total Volume （BV/TV，t=9.473，P<0.001） and trabecular thickness （Tb.Th） （t=18.64，P<0.001），while significantly reduced trabecular spacing （Tb.Sp，t=7.794，P<0.01）. The double fluorescent labeling showed that the mineral appo-sition rate （MAR） of bone mineralization was significantly increased after PTH （1-34） treatment （t=29.99，P<0.001）. Von Kossa staining showed that the Von Kossa Area （VK. A） was significantly increased in the PTH （1-34） treatment group （t=2.914，P<0.05）. Mason- ing showed that the collagen volume fraction （CVF） was significantly increased after PTH （1-34） treatment （t=13.94，P<0.001）. Conclusion：PTH （1-34） can effectively induce bone mineralization in mice，and successfully construct an experimental animal model of bone mineralization in mice.

参考文献/References:

[1] ITOH Y，ITOH S，NARUSE H，et al. Intracellular density is a novel indicator of differentiation stages of murine osteoblast lineage cells[J]. J Cell Biochem，2021，122（12）：1805-1816.
[2] ROEDER E，MATTHEWS B ，KALAJZIC I. Visual reporters for study of the osteoblast lineage[J]. Bone，2016，92：189-195.
[3] KOMORI T. Regulation of proliferation，differentiation and functions of osteoblasts by Runx2[J]. Int J Mol Sci，2019，20（7）：1694.
[4] LIU Q，LI M，WANG S，et al. Recent advances of osterix transcription factor in osteoblast differentiation and bone formation[J]. Front Cell Dev Biol，2020，8：601224.
[5] WEI Y，TANG C，ZHANG J，et al. Extracellular vesicles derived from the mid-to-late stage of osteoblast differentiation markedly enhance osteogenesis in vitro and in vivo[J]. Biochem Biophys Res Commun，2019，514（1）：252-258.
[6] ROSCHGER P，MISOF B，PASCHALIS E，et al. Changes in the degree of mineralization with osteoporosis and its treatment[J]. Curr Osteoporos Rep，2014，12（3）：338-350.
[7] FISCHER V，HAFFNER-LUNTZER M. Interaction between bone and immune cells：implications for postmenopausal osteoporosis[J]. Semin Cell Dev Biol，2022，123：14-21.
[8] KAMENICK?譭 P，BRIOT K，MUNNS C F，et al. X-linked hypophosphataemia[J]. Lancet，2024，404（10455）：887-901.
[9] SWAMI S，JOHNSON J，BETTINSON L A，et al. Prevention of breast cancer skeletal metastases with parathyroid hormone[J]. JCI Insight，2017，2（17）：e90874.
[10] SWAMI S，ZHU H，NISCO A，et al. Parathyroid hormone 1 receptor signaling mediates breast cancer metastasis to bone in mice[J]. JCI Insight，2023，8（5）：e157390.
[11] CHOI S，WHITMAN M A，SHIMPI A A，et al. Bone-matrix mineralization dampens integrin-mediated mechanosignalling and meta-static progression in breast cancer[J]. Nat Biomed Eng，2023，7（11）：1455-1472.
[12] QASEEM A，HICKS L A，ETXEANDIA-IKOBALTZETA I，et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults：a living clinical guideline from the american college of physicians[J]. Ann Intern Med，2023，176（2）：224-238.
[13] MINISOLA S，CIPRIANI C，GROTTA G D，et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis[J]. Ther Adv Musculoskelet Dis，2019，11：1759720x19877994.
[14] ZHANG J，COHEN A，SHEN B，et al. The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin[J]. Proc Natl Acad Sci U S A，2021，118（25）：e2026176118.
[15] BALANI D H，ONO N，KRONENBERG H M. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo[J]. J Clin Invest，2017，127（9）：3327-3338.
[16] WENG S J，YAN D Y，GU L J，et al. Combined treatment with vitamin K2 and PTH enhanced bone formation in ovariectomized rats and increased differentiation of osteoblast in vivo[J]. Chem Biol Interact，2019，300：101-110.
[17] ZHANG K，WANG M，LI Y，et al. The PERK-EIF2α-ATF4 signaling branch regulates osteoblast differentiation and proliferation by PTH[J]. Am J Physiol Endocrinol Metab，2019，316（4）：E590-E604.
[18] BARANOWSKY A，JAHN D，JIANG S，et al. Procalcitonin is expressed in osteoblasts and limits bone resorption through inhibition of macrophage migration during intermittent PTH treatment[J]. Bone Res，2022，10（1）：9.
[19] CIVITELLI R，HRUSKA K A，JEFFREY J J，et al. Second messenger signaling in the regulation of collagenase production by osteogenic sarcoma cells[J]. Endocrinology，1989，124（6）：2928-2934.
[20] ZHU W，YANG M L，YANG G Y，et al. Changes in serum runt-related transcription factor 2 levels after a 6-month treatment with recombinant human parathyroid hormone in patients with osteoporosis[J]. J Endocrinol Invest，2012，35（6）：602-606.
[21] SMITH B J，CROCKETT E K，CHONGWATPOL P，et al. Montmorency tart cherry protects against age-related bone loss in female C57BL/6 mice and demonstrates some anabolic effects[J]. Eur J Nutr，2019，58（8）：3035-3046.
[22] BLOUIN S，KHANI F，MESSMER P，et al. Vitamin C deficiency deteriorates bone microarchitecture and mineralization in a sexspe-cific manner in adult mice[J]. J Bone Miner Res，2023，38（10）：1509-1520.
[23] DLUGOSOVA S，SPOUTIL F，MADUREIRA TRUFEN C E，et al. Skeletal dysmorphology and mineralization defects in Fgf20 KO mice[J]. Front Endocrinol （Lausanne），2024，15：1286365.
[24] ANDERSON P H. Vitamin D activity and metabolism in bone[J]. Curr Osteoporos Rep，2017，15（5）：443-449.
[25] VAN DRIEL M，VAN LEEUWEN J. Vitamin D endocrinology of bone mineralization[J]. Mol Cell Endocrinol，2017，453：46-51.
[26] EMCH M J，WICIK Z，ASPROS KGM，et al. Estrogen-regulated miRs in bone enhance osteoblast differentiation and matrix mineralization[J]. Mol Ther Nucleic Acids，2023，33：28-41.
[27] FRANK G R. The role of estrogen in pubertal skeletal physiology：epiphyseal maturation and mineralization of the skeleton[J]. Acta Paediatr，1995，84（6）：627-630.
[28] SHIMIZU E，SELVAMURUGAN N，WESTENDORF J J，et al. Parathyroid hormone regulates histone deacetylases in osteoblasts[J]. Ann N Y Acad Sci，2007，1116：349-353.

相似文献/References:

备注/Memo

备注/Memo:

基金项目:天津市医学重点科学（专科）建设项目（TJYXZDXK- 009A） 作者简介 王红丽（1999-），女，硕士在读，研究方向：肿瘤生物化学与分子生物学；通信作者：李晓青，E-mail：xqli@tmu.edu.cn。

常用功能

更新日期/Last Update: 2025-03-20